- People with a gene that has been turned off through a natural process maybe at higher risk of heart and blood-vessel disease.
- The affected gene, called CPT1A, makes a liver enzyme which, at low levels, is linked to increased risk factors for heart and blood-vessel disease.
- Evaluating CPT1A as a new genetic biomarker may one day identify people at the greatest risk for developing heart disease.
Two known biomarkers are high blood levels of certain fats – low-density lipoproteins (“bad” cholesterol) and high triglycerides. Another recognized biomarker is a protein called adiponectin, which is made in fat tissue and helps regulate the process of turning food into energy. At low levels it is associated with increased disease risk.
Researchers examined these biomarkers in relation to a particular gene, called CPT1A in 888 patients from the Genetics of Lipid-Lowering Drugs and Diet Network study. The gene makes a liver enzyme that helps break down fat in food.
They also monitored a biochemical process called methylation that switches off genes. During this process carbon and hydrogen atoms combine to form a compound called a methyl group, which binds to a portion of a gene and turns off its activity.
“Our results open the door to the development of new screening tools and a clearer understanding of the biological mechanisms that underlie heart disease,” said Stella Aslibekyan, Ph.D., study lead author and assistant professor at the University of Alabama at Birmingham.
They found that patients who had methyl groups bound to CPT1A had significantly higher triglycerides and low-density lipoprotein levels, and lower adiponectin.
Heart disease is the number one killer among adults in the United States, and researchers are trying to identify individual genetic differences that might increase risk. One way to do this is by studying subtle variations in indicators of disease, or biomarkers, to identify people who are at greatest risk for developing heart disease.
“This is one step on the road to personalized medicine,” Aslibekyan said. “In the future, we may be able to screen for methylation of CPT1A to identify at-risk individuals.”
Co-authors are Marguerite M. Irvin, Ph.D.; Jin Sha, M.S.; Degui Zhi, Ph.D.; Krista Stanton Thibeault, M.S.; Michael Y. Tsai, M.D., Ph.D.; Paul N. Hopkins, M.D.; Ingrid B. Borecki, Ph.D.; Jose M. Ordovas, Ph.D.; Devin M. Absher, Ph.D.; and Donna K. Arnett, Ph.D.
The National Institutes of Health funded the study.
Statements and conclusions of study authors published in American Heart Association scientific journals or presented at American Heart Association conferences are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
Additional resources, including multimedia, are available in the right column of this link: http://newsroom.heart.org/news/genetic-off-switch-linked-to-increased-risk-factors-for-heart-disease?preview=3ade8c330d41e626b95974d5792414dd
Emerging Science Series, a free online webinar presentation.
View the webinar at www.scientificsessions.org/emergingscience.